These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 9272412)
1. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Lukkari E; Juhakoski A; Aranko K; Neuvonen PJ Eur J Clin Pharmacol; 1997; 52(5):403-6. PubMed ID: 9272412 [TBL] [Abstract][Full Text] [Related]
2. Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet. Lukkari E; Aranko K; Juhakoski A; Hakonen T; Neuvonen PJ Pharmacol Toxicol; 1997 Jul; 81(1):31-4. PubMed ID: 9258982 [TBL] [Abstract][Full Text] [Related]
3. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Sathyan G; Chancellor MB; Gupta SK Br J Clin Pharmacol; 2001 Oct; 52(4):409-17. PubMed ID: 11678784 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. Gupta SK; Sathyan G J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329 [TBL] [Abstract][Full Text] [Related]
6. Effect of food on the bioavailability of oxybutynin from a controlled release tablet. Lukkari E; Castrèn-Kortekangas P; Juhakoski A; Löyttyniemi E; Aranko K; Neuvonen PJ Eur J Clin Pharmacol; 1996; 50(3):221-3. PubMed ID: 8737763 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567 [TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids. Lukkari E; Hakonen T; Neuvonen PJ Eur J Clin Pharmacol; 1998 Jan; 53(5):351-4. PubMed ID: 9516036 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591 [TBL] [Abstract][Full Text] [Related]
11. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Neuvonen PJ; Kantola T; Kivistö KT Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477 [TBL] [Abstract][Full Text] [Related]
12. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Varis T; Kaukonen KM; Kivistö KT; Neuvonen PJ Clin Pharmacol Ther; 1998 Oct; 64(4):363-8. PubMed ID: 9797792 [TBL] [Abstract][Full Text] [Related]
13. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Kaukonen KM; Olkkola KT; Neuvonen PJ Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703 [TBL] [Abstract][Full Text] [Related]
14. Sensitive determination of oxybutynin and desethyloxybutynin in dog plasma by LC-ESI/MS/MS. Kim H; Han SB J Pharm Biomed Anal; 2003 Feb; 31(2):341-9. PubMed ID: 12609673 [TBL] [Abstract][Full Text] [Related]
15. Effect of itraconazole on the pharmacokinetics of atorvastatin. Kantola T; Kivistö KT; Neuvonen PJ Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720 [TBL] [Abstract][Full Text] [Related]
16. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Neuvonen PJ; Jalava KM Clin Pharmacol Ther; 1996 Jul; 60(1):54-61. PubMed ID: 8689812 [TBL] [Abstract][Full Text] [Related]